Roche Evrysdi shows improved motor function in babies and safety in SMA

 

• Data from JEWELFISH, the first trial in a diverse population aged 1 to 60 years with SMA who received prior treatment, showed a consistent safety profile and >2-fold increase in SMN protein levels
• Pre-symptomatic babies with SMA treated with Evrysdi for at least one year were able to sit, stand and walk in preliminary data from RAINBOWFISH study
• Evrysdi has proven efficacy in adults, children and babies two months and older and is now approved in 44 countries worldwide

https://www.globenewswire.com/news-release/2021/06/11/2245634/0/en/New-Roche-data-for-Evrysdi-show-improved-motor-function-in-pre-symptomatic-babies-after-one-year-and-confirm-safety-profile-in-previously-treated-people-with-spinal-muscular-atroph.html